

Moberg Pharma - Exciting year ahead

Redeye sees a Q4 report that was uneventful as expected. The highlight for the year is the expected EU regulatory approval during 2023e. The long-term outlook for MOB-015 still looks bright. We see that Moberg Pharma is progressing as planned, and the EU approval during 2023 should be an important catalyst as we advance.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Moberg Pharma - Exciting year ahead